{"protocolSection":{"identificationModule":{"nctId":"NCT05706506","orgStudyIdInfo":{"id":"18520"},"secondaryIdInfos":[{"id":"I8F-MC-GPIL","type":"OTHER","domain":"Eli Lilly and Company"},{"id":"2022-002708-18","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)","officialTitle":"An Open-Label, Single-Arm, Phase 4 Study to Assess Glycemic Control When Adults With Type 2 Diabetes Switch From a GLP-1 RA to Tirzepatide (SURPASS-SWITCH-2)"},"statusModule":{"statusVerifiedDate":"2024-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-03-08","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-10-31","type":"ACTUAL"},"completionDateStruct":{"date":"2023-10-31","type":"ACTUAL"},"studyFirstSubmitDate":"2023-01-23","studyFirstSubmitQcDate":"2023-01-23","studyFirstPostDateStruct":{"date":"2023-01-31","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-10-30","resultsFirstSubmitQcDate":"2024-12-10","resultsFirstPostDateStruct":{"date":"2024-12-13","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-12-10","lastUpdatePostDateStruct":{"date":"2024-12-13","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide (GIP) GLP-1 RA agonist in participants with type 2 diabetes (T2D)."},"conditionsModule":{"conditions":["Type 2 Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":152,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"5 milligrams (mg) Tirzepatide","type":"EXPERIMENTAL","description":"Participants received 5 mg tirzepatide subcutaneously administered once weekly for 12 weeks.","interventionNames":["Drug: Tirzepatide"]}],"interventions":[{"type":"DRUG","name":"Tirzepatide","description":"Administered SC","armGroupLabels":["5 milligrams (mg) Tirzepatide"],"otherNames":["LY3298176"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c)","description":"HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.","timeFrame":"Baseline, Week 12"}],"secondaryOutcomes":[{"measure":"Change From Baseline in Percentage of Time Per Day That Continuous Glucose Monitoring (CGM)-Derived Values Were >180 Milligram/Deciliter (mg/dl) (10 Millimole/Liter (mmol/L))","description":"Change from Baseline in Percentage of Time per Day that CGM-derived Values were \\>180 mg/dl (10 mmol/L) was assessed.","timeFrame":"Baseline, Week 4"},{"measure":"Change From Baseline in Percentage of Time Per Day That CGM-derived Values Were >180 mg/dl (10 mmol/L)","description":"Change from Baseline in Percentage of Time per Day that CGM-derived Values were \\>180 mg/dl (10 mmol/L) was assessed.","timeFrame":"Baseline, Week 12"},{"measure":"Change From Baseline in Duration of Time in Minutes Per Day That CGM Derived Values Were >180 mg/dl (10 mmol/L)","description":"Change from Baseline in Duration of Time in Minutes per Day that CGM derived Values were \\>180 mg/dl (10 mmol/L) was assessed.","timeFrame":"Baseline, Week 4"},{"measure":"Change From Baseline in Duration of Time in Minutes Per Day That CGM Derived Values Were >180 mg/dl (10 mmol/L)","description":"Change from Baseline in Duration of Time in Minutes per Day that CGM derived Values were \\>180 mg/dl (10 mmol/L) was assessed.","timeFrame":"Baseline, Week 12"},{"measure":"Change From Baseline in Fasting Serum Glucose (FSG)","description":"Change from Baseline in FSG was assessed.","timeFrame":"Baseline, Week 12"},{"measure":"Change From Baseline in Weight","description":"Change from Baseline in Weight was assessed.","timeFrame":"Baseline, Week 12"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have Type 2 diabetes (T2D)\n* Have an HbA1c c ≥6.5% (≥48 mmol/mol) to ≤9.0% (≤75 mmol/mol)\n* Have a body mass index (BMI) ≥25 kilogram per square meter (kg/m²) at screening\n* Have been on a stable treatment dose of 1 of the listed GLP-1 RAs for ≥3 months\n* No treatment with oral antidiabetic medicine (OAM) or on stable doses (for at least 3 months before screening) of up to 3 OAM. The OAM may include metformin, sodium-glucose linked transporter-2 inhibitor (SGLT-2i), thiazolidinediones, or α-glucosidase inhibitors.\n\nExclusion Criteria:\n\n* Have Type 1 Diabetes (T1D)\n* Have a clinical history of\n\n  * proliferative diabetic retinopathy\n  * diabetic maculopathy, or\n  * non-proliferative diabetic retinopathy that requires acute treatment\n* Are at high risk for cardiovascular disease or have a history of\n\n  * myocardial infarction\n  * percutaneous coronary revascularization procedure\n  * carotid stenting or surgical revascularization\n  * nontraumatic amputation\n  * peripheral vascular procedure\n  * cerebrovascular accident\n  * or hospitalization for congestive heart failure\n* Have New York Heart Association (NYHA) Functional Classification Class IV congestive heart failure\n* Have a history of ketoacidosis or hyperosmolar state or coma\n* Have a history of severe hypoglycemia or hypoglycemia unawareness within the 6 months.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Fiel Family and Sports Medicine PC","city":"Tempe","state":"Arizona","zip":"85283","country":"United States","geoPoint":{"lat":33.41477,"lon":-111.90931}},{"facility":"New Hope Research Development","city":"Corona","state":"California","zip":"92882","country":"United States","geoPoint":{"lat":33.87529,"lon":-117.56644}},{"facility":"Velocity Clinical Research, Gardena","city":"Gardena","state":"California","zip":"90247","country":"United States","geoPoint":{"lat":33.88835,"lon":-118.30896}},{"facility":"Velocity Clinical Research, Huntington Park","city":"Huntington Park","state":"California","zip":"90255","country":"United States","geoPoint":{"lat":33.98168,"lon":-118.22507}},{"facility":"Velocity Clinical Research, Huntington Park","city":"Los Angeles","state":"California","zip":"90057","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Valley Clinical Trials, Inc.","city":"Northridge","state":"California","zip":"91325","country":"United States","geoPoint":{"lat":34.22834,"lon":-118.53675}},{"facility":"Dream Team Clinical Research","city":"Pomona","state":"California","zip":"91767","country":"United States","geoPoint":{"lat":34.05529,"lon":-117.75228}},{"facility":"Scripps Whittier Diabetes Institute","city":"San Diego","state":"California","zip":"92121-1520","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Metabolic Institute of America","city":"Tarzana","state":"California","zip":"91356-3551","country":"United States","geoPoint":{"lat":34.17334,"lon":-118.55397}},{"facility":"CMR of Greater New Haven, LLC","city":"Waterbury","state":"Connecticut","zip":"06708","country":"United States","geoPoint":{"lat":41.55815,"lon":-73.0515}},{"facility":"Velocity Clinical Research, Hallandale Beach","city":"Hallandale","state":"Florida","zip":"33009","country":"United States","geoPoint":{"lat":25.9812,"lon":-80.14838}},{"facility":"East Coast Institute for Research, LLC","city":"Jacksonville","state":"Florida","zip":"32204","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Florida Institute For Clinical Research, LLC","city":"Orlando","state":"Florida","zip":"32825","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"New Tampa Health","city":"Tampa","state":"Florida","zip":"33603-3402","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Georgia Clinical Research","city":"Lawrenceville","state":"Georgia","zip":"30044-5896","country":"United States","geoPoint":{"lat":33.95621,"lon":-83.98796}},{"facility":"Endocrine Research Solutions, Inc.","city":"Roswell","state":"Georgia","zip":"30076","country":"United States","geoPoint":{"lat":34.02316,"lon":-84.36159}},{"facility":"Velocity Clinical Research, Valparaiso","city":"Valparaiso","state":"Indiana","zip":"46383","country":"United States","geoPoint":{"lat":41.47309,"lon":-87.06114}},{"facility":"Iowa Diabetes and Endocrinology Research Center","city":"West Des Moines","state":"Iowa","zip":"50265","country":"United States","geoPoint":{"lat":41.57721,"lon":-93.71133}},{"facility":"Cotton O'Neil Clinic","city":"Topeka","state":"Kansas","zip":"66606","country":"United States","geoPoint":{"lat":39.04833,"lon":-95.67804}},{"facility":"Versailles Family Medicine","city":"Versailles","state":"Kentucky","zip":"40383-1947","country":"United States","geoPoint":{"lat":38.05258,"lon":-84.72995}},{"facility":"Endocrine and Metabolic Consultants","city":"Rockville","state":"Maryland","zip":"20852","country":"United States","geoPoint":{"lat":39.084,"lon":-77.15276}},{"facility":"Clinical Research Professionals","city":"Chesterfield","state":"Missouri","zip":"63005","country":"United States","geoPoint":{"lat":38.66311,"lon":-90.57707}},{"facility":"Clinical Research of South Nevada","city":"Las Vegas","state":"Nevada","zip":"89121","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Palm Research Center Tenaya","city":"Las Vegas","state":"Nevada","zip":"89128","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Advanced Medical Research","city":"Maumee","state":"Ohio","zip":"43537-9402","country":"United States","geoPoint":{"lat":41.56283,"lon":-83.65382}},{"facility":"Conrad Clinical Research","city":"Edmond","state":"Oklahoma","zip":"73013","country":"United States","geoPoint":{"lat":35.65283,"lon":-97.4781}},{"facility":"Mountain View Clinical Research, Inc.","city":"Greenville","state":"South Carolina","zip":"29607","country":"United States","geoPoint":{"lat":34.85262,"lon":-82.39401}},{"facility":"Texas Diabetes & Endocrinology, P.A.","city":"Austin","state":"Texas","zip":"78731-4309","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"North Texas Endocrine Center","city":"Dallas","state":"Texas","zip":"75231","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Memorial City Endocrine Consultants","city":"Houston","state":"Texas","zip":"77043-2742","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Consano Clinical Research, LLC","city":"Shavano Park","state":"Texas","zip":"78231","country":"United States","geoPoint":{"lat":29.58495,"lon":-98.55252}},{"facility":"ClinPoint Trials","city":"Waxahachie","state":"Texas","zip":"75165","country":"United States","geoPoint":{"lat":32.38653,"lon":-96.84833}}]},"referencesModule":{"seeAlsoLinks":[{"label":"A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)","url":"https://trials.lilly.com/en-US/trial/385077"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.","accessCriteria":"A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.","url":"http://vivli.org"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"5 Milligrams (mg) Tirzepatide","description":"Participants received 5 mg tirzepatide subcutaneously (SC) administered once weekly (QW) for 12 weeks."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"152"}]},{"type":"Received At Least 1 Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"152"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"131"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"21"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"4"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"Inadvertent Enrolment","reasons":[{"groupId":"FG000","numSubjects":"12"}]},{"type":"Early Discontinuation Due to Hyperglycemia","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Participant Moved Out of State","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All participants who received at least one dose of tirzepatide.","groups":[{"id":"BG000","title":"5 mg Tirzepatide","description":"Participants received 5 mg tirzepatide SC administered QW for 12 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"152"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"58.1","spread":"10.17"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"84"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"68"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"32"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"120"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"2"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"9"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"24"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"117"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"152"}]}]}]},{"title":"Hemoglobin A1c (HbA1c)","description":"HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Percentage of HbA1c","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7.40","spread":"0.660"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (HbA1c)","description":"HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.","populationDescription":"All participants who received at least one dose of tirzepatide, had a baseline and had evaluable data for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percentage of HbA1c","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"5 mg Tirzepatide","description":"Participants received 5 mg tirzepatide SC administered QW for 12 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.43","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Percentage of Time Per Day That Continuous Glucose Monitoring (CGM)-Derived Values Were >180 Milligram/Deciliter (mg/dl) (10 Millimole/Liter (mmol/L))","description":"Change from Baseline in Percentage of Time per Day that CGM-derived Values were \\>180 mg/dl (10 mmol/L) was assessed.","populationDescription":"All participants who received at least one dose of tirzepatide, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percentage of time per day","timeFrame":"Baseline, Week 4","groups":[{"id":"OG000","title":"5 mg Tirzepatide","description":"Participants received 5 mg tirzepatide SC administered QW for 12 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.52","spread":"1.55"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Percentage of Time Per Day That CGM-derived Values Were >180 mg/dl (10 mmol/L)","description":"Change from Baseline in Percentage of Time per Day that CGM-derived Values were \\>180 mg/dl (10 mmol/L) was assessed.","populationDescription":"All participants who received at least one dose of tirzepatide, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percentage of time per day","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"5 mg Tirzepatide","description":"Participants received 5 mg tirzepatide SC administered QW for 12 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.37","spread":"1.54"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Duration of Time in Minutes Per Day That CGM Derived Values Were >180 mg/dl (10 mmol/L)","description":"Change from Baseline in Duration of Time in Minutes per Day that CGM derived Values were \\>180 mg/dl (10 mmol/L) was assessed.","populationDescription":"All participants who received at least one dose of tirzepatide, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Minutes per day","timeFrame":"Baseline, Week 4","groups":[{"id":"OG000","title":"5 mg Tirzepatide","description":"Participants received 5 mg tirzepatide SC administered QW for 12 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-93.82","spread":"22.30"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Duration of Time in Minutes Per Day That CGM Derived Values Were >180 mg/dl (10 mmol/L)","description":"Change from Baseline in Duration of Time in Minutes per Day that CGM derived Values were \\>180 mg/dl (10 mmol/L) was assessed.","populationDescription":"All participants who received at least one dose of tirzepatide, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Minutes per day","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"5 mg Tirzepatide","description":"Participants received 5 mg tirzepatide SC administered QW for 12 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-106.09","spread":"22.21"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Serum Glucose (FSG)","description":"Change from Baseline in FSG was assessed.","populationDescription":"All participants who received at least one dose of tirzepatide, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"milligrams per deciliter (mg/dL)","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"5 mg Tirzepatide","description":"Participants received 5 mg tirzepatide SC administered QW for 12 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.83","spread":"2.85"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Weight","description":"Change from Baseline in Weight was assessed.","populationDescription":"All participants who received at least one dose of tirzepatide, had a baseline and at least one post-baseline value for this outcome.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kilograms (kg)","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"5 mg Tirzepatide","description":"Participants received 5 mg tirzepatide SC administered QW for 12 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.15","spread":"0.28"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Baseline Up To 12 Weeks","description":"All participants who received at least one dose of tirzepatide.","eventGroups":[{"id":"EG000","title":"5 mg Tirzepatide","description":"Participants received 5 mg tirzepatide SC administered QW for 12 weeks.","deathsNumAffected":0,"deathsNumAtRisk":152,"seriousNumAffected":1,"seriousNumAtRisk":152,"otherNumAffected":0,"otherNumAtRisk":152}],"seriousEvents":[{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":152}]},{"term":"Wound dehiscence","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":152}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","email":"ClinicalTrials.gov@lilly.com","phone":"800-545-5979"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2022-08-26","uploadDate":"2024-10-22T02:03","filename":"Prot_000.pdf","size":848529},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2023-09-19","uploadDate":"2024-10-22T02:04","filename":"SAP_001.pdf","size":539910}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2024-11-25","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"}],"ancestors":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000098860","term":"Tirzepatide"}],"ancestors":[{"id":"D000067757","term":"Glucagon-Like Peptide-1 Receptor"},{"id":"D000067756","term":"Glucagon-Like Peptide Receptors"},{"id":"D043562","term":"Receptors, G-Protein-Coupled"},{"id":"D011956","term":"Receptors, Cell Surface"},{"id":"D008565","term":"Membrane Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D011964","term":"Receptors, Gastrointestinal Hormone"},{"id":"D018000","term":"Receptors, Peptide"}]}},"hasResults":true}